Compare QRVO & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QRVO | BIO |
|---|---|---|
| Founded | 1957 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 8.2B |
| IPO Year | 1997 | N/A |
| Metric | QRVO | BIO |
|---|---|---|
| Price | $86.90 | $321.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | $98.23 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 882.5K | 146.2K |
| Earning Date | 01-27-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $3,663,072,000.00 | $2,557,500,000.00 |
| Revenue This Year | $3.36 | $1.62 |
| Revenue Next Year | $2.39 | $2.26 |
| P/E Ratio | $37.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $49.46 | $211.43 |
| 52 Week High | $106.30 | $373.69 |
| Indicator | QRVO | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 63.13 |
| Support Level | $84.50 | $300.26 |
| Resistance Level | $87.50 | $305.62 |
| Average True Range (ATR) | 1.56 | 7.83 |
| MACD | 0.00 | 1.32 |
| Stochastic Oscillator | 52.69 | 97.97 |
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.